Pembrolizumab (pembro) in heavily pretreated metastatic castrate-resistant prostate cancer (mCRPC).

被引：0
|
作者：
Moses, Marcus Marie
Ledet, Elisa
Manogue, Charlotte
Lewis, Brian E.
Barata, Pedro C.
Sartor, A. Oliver
Layton, Jodi Lyn
机构：
[1] Tulane Univ, New Orleans, LA 70118 USA
[2] Tulane Univ, Ctr Canc, New Orleans, LA 70118 USA
[3] Tulane Univ, Sch Med, 1430 Tulane Ave, New Orleans, LA 70112 USA
[4] Tulane Med Sch, New Orleans, LA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 07期
关键词：
D O I：
10.1200/JCO.2019.37.7_suppl.255
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
255
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Abiraterone in heavily pretreated patients with metastatic castrate-resistant prostate cancer
    Francini, Edoardo
    Fiaschi, Anna Ida
    Petrioli, Roberto
    Francini, Filippo
    Bianco, Vincenzo
    Perrella, Armando
    Paganini, Giovanni
    Laera, Letizia
    Roviello, Giandomenico
    [J]. ANTI-CANCER DRUGS, 2014, 25 (04) : 472 - 477
  • [2] Pembrolizumab in men with heavily treated metastatic castrate-resistant prostate cancer
    Tucker, Matthew D.
    Zhu, Jason
    Marin, Daniele
    Gupta, Rajan T.
    Gupta, Santosh
    Berry, William R.
    Ramalingam, Sundhar
    Zhang, Tian
    Harrison, Michael
    Wu, Yuan
    Healy, Patrick
    Lisi, Stacey
    George, Daniel J.
    Armstrong, Andrew J.
    [J]. CANCER MEDICINE, 2019, 8 (10): : 4644 - 4655
  • [3] Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
    Karnes, R. Jeffrey
    Ahmed, Mohamed E.
    [J]. APPLIED RADIOLOGY, 2021, 50 (01) : 42 - 43
  • [4] Keynote-365 cohort a: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).
    Yu, Evan Y.
    Massard, Christophe
    Retz, Margitta
    Tafreshi, Ali
    Carles Galceran, Joan
    Hammerer, Peter
    Fong, Peter C. C.
    Shore, Neal D.
    Joshua, Anthony
    Linch, Mark David
    Gurney, Howard
    Romano, Emanuela
    Augustin, Marinela
    Piulats, Josep M.
    Wu, Haiyan
    Schloss, Charles
    Poehlein, Christian Heinrich
    De Bono, Johann S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [5] Radium-223 in Heavily Pretreated Metastatic Castrate-Resistant Prostate Cancer
    Modi, Dipenkumar
    Hwang, Clara
    Mamdani, Hirva
    Kim, Seongho
    Gayar, Hesham
    Vaishampayan, Ulka
    Joyrich, Richard
    Heath, Elisabeth I.
    [J]. CLINICAL GENITOURINARY CANCER, 2016, 14 (05) : 373 - 380
  • [6] KEYNOTE-365 cohort C updated results: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)
    Berry, William R.
    Fong, Peter C. C.
    Piulats, Josep M.
    Appleman, Leonard Joseph
    Conter, Henry Jacob
    Feyerabend, Susan
    Shore, Neal D.
    Gravis, Gwenaelle
    Laguerre, Brigitte
    Gurney, Howard
    Retz, Margitta
    Romano, Emanuela
    Mourey, Loic
    De Bono, Johann S.
    Kam, Audrey E.
    Emmenegger, Urban
    Wu, Helen
    Schloss, Charles
    Poehlein, Christian Heinrich
    Yu, Evan Y.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [7] Abiraterone in heavily pretreated patients with metastatic castrate-resistant prostate cancer: final analysis of overall survival
    Francini, Edoardo
    Fiaschi, Anna I.
    Petrioli, Roberto
    Bianco, Vincenzo
    Laera, Letizia
    Francini, Filippo
    Roviello, Giandomenico
    [J]. ANTI-CANCER DRUGS, 2015, 26 (08) : 910 - 911
  • [8] Continuous IV Infusion of 5-Flourouracil in Heavily Pretreated Metastatic Castrate-Resistant Prostate Cancer
    Manogue, Charlotte
    Fleming, William
    Ledet, Elisa
    Jaeger, Ellen
    Layton, Jodi
    Barata, Pedro
    Lewis, Brian
    Sartor, Oliver
    [J]. CLINICAL GENITOURINARY CANCER, 2022, 20 (06) : 586 - 590
  • [9] Use of radium-223 in heavily pretreated metastatic castrate resistant prostate cancer (mCRPC) patients.
    Modi, Dipenkumar
    Kim, SeongHo
    Mamdani, Hirva Mansurali
    Hwang, Clara
    Gayar, Hersham
    Vaishampayan, Ulka N.
    Joyrich, Richard
    Heath, Elisabeth I.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [10] Impact of comorbidity on outcome in men with metastatic castrate-resistant prostate cancer (mCRPC)
    Zist, A.
    Amir, E.
    Ocana, A.
    Seruga, B.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S703 - S703
12345